These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 20581879)

  • 1. Prospective comparison of PCR-based vs late mRNA-based preemptive antiviral therapy for HCMV infection in patients after allo-SCT.
    Hebart H; Lengerke C; Ljungman P; Paya CV; Klingebiel T; Loeffler J; Pfaffenrath S; Lewensohn-Fuchs I; Barkholt L; Tomiuk J; Meisner C; Lunenberg J; Top B; Razonable RR; Patel R; Litzow MR; Jahn G; Einsele H
    Bone Marrow Transplant; 2011 Mar; 46(3):408-15. PubMed ID: 20581879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation.
    Hebart H; Rudolph T; Loeffler J; Middeldorp J; Ljubicic T; Jahn G; Einsele H
    Bone Marrow Transplant; 2002 Aug; 30(3):181-7. PubMed ID: 12189537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human cytomegalovirus pp67 mRNAemia versus pp65 antigenemia for guiding preemptive therapy in heart and lung transplant recipients: a prospective, randomized, controlled, open-label trial.
    Gerna G; Baldanti F; Lilleri D; Parea M; Torsellini M; Castiglioni B; Vitulo P; Pellegrini C; Viganò M; Grossi P; Revello MG
    Transplantation; 2003 Apr; 75(7):1012-9. PubMed ID: 12698090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HCMV pp67-mRNA detection by nucleic acid sequence-based amplification in renal transplant patients.
    Merlino C; Bergallo M; Gregori G; Sinesi F; Bollero C; Cavallo R
    New Microbiol; 2002 Jan; 25(1):1-8. PubMed ID: 11837384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary report for the application of nucleic acid sequence-based amplification in detection of human cytomegalovirus (HCMV) late pp67 mRNA for diagnosis of HCMV infection.
    Pairoj W; Srichunrusami C; Chantratita W; Bodhiphala P; Sungkanuparph S; Vibhagool A
    J Med Assoc Thai; 2000 Mar; 83 Suppl 1():S28-34. PubMed ID: 10865403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study.
    Gerna G; Baldanti F; Torsellini M; Minoli L; Viganò M; Oggionnis T; Rampino T; Castiglioni B; Goglio A; Colledan M; Mammana C; Nozza F; Daniele L;
    Antivir Ther; 2007; 12(1):63-72. PubMed ID: 17503749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saliva as a source of HCMV DNA in allogeneic stem cell transplantation patients.
    Correia-Silva JF; Bruna-Romero O; Resende RG; Miranda LP; Oliveira FE; Costa FO; Xavier SG; Figueiredo-Neves SP; Almeida HC; Bittencourt H; Gomez RS
    Oral Dis; 2010 Mar; 16(2):210-6. PubMed ID: 20374507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a quantitative-competitive PCR for quantification of human cytomegalovirus load and comparison with antigenaemia, viraemia and pp67 RNA detection by nucleic acid sequence-based amplification.
    Bergallo M; Costa C; Tarallo S; Daniele R; Merlino C; Segoloni GP; Negro Ponzi A; Cavallo R
    Panminerva Med; 2006 Jun; 48(2):119-27. PubMed ID: 16953149
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
    Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
    Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection.
    Einsele H; Hebart H; Kauffmann-Schneider C; Sinzger C; Jahn G; Bader P; Klingebiel T; Dietz K; Löffler J; Bokemeyer C; Müller CA; Kanz L
    Bone Marrow Transplant; 2000 Apr; 25(7):757-63. PubMed ID: 10745262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended routine polymerase chain reaction surveillance and pre-emptive antiviral therapy for cytomegalovirus after allogeneic transplantation.
    Peggs KS; Preiser W; Kottaridis PD; McKeag N; Brink NS; Tedder RS; Goldstone AH; Linch DC; Mackinnon S
    Br J Haematol; 2000 Dec; 111(3):782-90. PubMed ID: 11122138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Application of real time polymerase chain reaction to the diagnosis and treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation].
    Chen H; Liu KY; Xu LP; Liu DH; Chen YH; Zhao XS; Yu L; Han W; Zhang XH; Wang Y; Chen Y; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):77-81. PubMed ID: 19563015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients.
    Ljungman P; Loré K; Aschan J; Klaesson S; Lewensohn-Fuchs I; Lönnqvist B; Ringdén O; Winiarski J; Ehrnst A
    Bone Marrow Transplant; 1996 Apr; 17(4):583-7. PubMed ID: 8722359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR.
    Schulenburg A; Watkins-Riedel T; Greinix HT; Rabitsch W; Loidolt H; Keil F; Mitterbauer M; Kalhs P
    Bone Marrow Transplant; 2001 Oct; 28(8):765-8. PubMed ID: 11781628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the COBAS Amplicor HCMV Monitor for early detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation.
    Lengerke C; Ljubicic T; Meisner C; Loeffler J; Sinzger C; Einsele H; Hebart H
    Bone Marrow Transplant; 2006 Jul; 38(1):53-60. PubMed ID: 16788683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay.
    Lo CY; Ho KN; Yuen KY; Lui SL; Li FK; Chan TM; Lo WK; Cheng IK
    Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression dynamics of human cytomegalovirus immune evasion genes US3, US6, and US11 in the blood of lung transplant recipients.
    Greijer AE; Verschuuren EA; Dekkers CA; Adriaanse HM; van der Bij W; The TH; Middeldorp JM
    J Infect Dis; 2001 Aug; 184(3):247-55. PubMed ID: 11443549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of CMV infection: a comparison of PCR from whole blood, plasma-PCR, pp65-antigenemia and virus culture in patients after bone marrow transplantation.
    Hebart H; Müller C; Löffler J; Jahn G; Einsele H
    Bone Marrow Transplant; 1996 May; 17(5):861-8. PubMed ID: 8733710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.
    Lilleri D; Baldanti F; Gatti M; Rovida F; Dossena L; De Grazia S; Torsellini M; Gerna G
    J Med Virol; 2004 Jul; 73(3):412-8. PubMed ID: 15170637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation.
    Gerna G; Lilleri D; Callegaro A; Goglio A; Cortese S; Stroppa P; Torre G
    Transplantation; 2008 Jul; 86(1):163-6. PubMed ID: 18622294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.